IPCIQ (IntelliPharmaCeutics International) Total Current Assets: $0.86 Mil (As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPCIQ IntelliPharmaCeutics International Inc IPCIQ
16 GF Score
Price $0.15
View Full Analysis

What is IntelliPharmaCeutics International Total Current Assets?

IntelliPharmaCeutics International IPCIQ -100.00% 16 Total Current Assets is $0.86 Mil as of Aug. 2023. GuruFocus rates IPCIQ with a GF Score™ of 16/100.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. IntelliPharmaCeutics International's total current assets for the quarter that ended in Aug. 2023 was $0.86 Mil.

IntelliPharmaCeutics International  (OTCPK:IPCIQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

IntelliPharmaCeutics International's Liquidation Value for the quarter that ended in Aug. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.4-14.442+0.75 * 0+0.5 * 0
=-14.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Total Current Assets Related Terms

IntelliPharmaCeutics International Total Current Assets Historical Data

* Premium members only.

The historical data trend for IntelliPharmaCeutics International's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Total Current Assets Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.72 1.52 1.48 1.10 0.49

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.49 0.74 0.95 0.86
IPCIQ
16GF Score
IntelliPharmaCeutics International Inc IPCIQ
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IntelliPharmaCeutics International Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

IntelliPharmaCeutics International's Total Current Assets for the fiscal year that ended in Nov. 2022 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.084+0.001+0+0.408
=0.49

IntelliPharmaCeutics International's Total Current Assets for the quarter that ended in Aug. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.4+0+0+0.462
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $0.86 Mil mean?
IntelliPharmaCeutics International (IPCIQ) has a Total Current Assets of $0.86 Mil as of Aug. 2023. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for IntelliPharmaCeutics International and its competitors.
Is IntelliPharmaCeutics International's Total Current Assets too high?
IntelliPharmaCeutics International's current Total Current Assets is $0.86 Mil. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's Total Current Assets compare to CHRO and KTTA?
IntelliPharmaCeutics International's Total Current Assets of $0.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for IntelliPharmaCeutics International and its competitors. IntelliPharmaCeutics International's current Total Current Assets is $0.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current Total Current Assets of $0.86 Mil. The current Total Current Assets is $0.86 Mil. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current Total Current Assets is $0.86 Mil as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IntelliPharmaCeutics International Business Description

Address 30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score

Get the complete analysis for IPCIQ

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price